Display Settings:

Format

Send to:

Choose Destination
    Int J Med Sci. 2011 Mar 23;8(3):245-53.

    Current status of methods to assess cancer drug resistance.

    Source

    Medical Faculty, University of Tübingen, Tübingen, Germany. Theodor-Lippert@web.de

    Abstract

    Drug resistance is the main cause of the failure of chemotherapy of malignant tumors, resistance being either preexisting (intrinsic resistance) or induced by the drugs (acquired resistance). At present, resistance is usually diagnosed during treatment after a long period of drug administration.In the present paper, methods for a rapid assessment of drug resistance are described. Three main classes of test procedures can be found in the literature, i.e. fresh tumor cell culture tests, cancer biomarker tests and positron emission tomography (PET) tests. The methods are based on the evaluation of molecular processes, i.e. metabolic activities of cancer cells. Drug resistance can be diagnosed before treatment in-vitro with fresh tumor cell culture tests, and after a short time of treatment in-vivo with PET tests. Cancer biomarker tests, for which great potential has been predicted, are largely still in the development stage. Individual resistance surveillance with tests delivering rapid results signifies progress in cancer therapy management, by providing the possibility to avoid drug therapies that are ineffective and only harmful.

    PMID:
    21487568
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3074090
    Free PMC Article

    Images from this publication.See all images (3) Free text

    Fig 2
    Fig 1
    Fig 3

      Supplemental Content

      Icon for Ivyspring International Publisher Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk